Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Baxter
McKesson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

JETREA Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: JETREA
Patents:8
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for JETREA
Recent Clinical Trials for JETREA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Universitaire Ziekenhuizen LeuvenPhase 1
Katholieke Universiteit LeuvenPhase 1
Alcon ResearchPhase 4

See all JETREA clinical trials

Pharmacology for JETREA
Ingredient-typePeptide Hydrolases

Company Disclosures: US Patents for JETREA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial Thromb-X nv (Leuven, BE) 2020-12-21 RX company
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial ThromboGenics NV (Leuven, BE) 2022-12-06 RX company
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial ThromboGenics NV (Heverlee, BE) 2022-12-06 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for JETREA

These patents were identified by searching patent claims

Supplementary Protection Certificates for JETREA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13C0052 France   Start Trial PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
122013000076 Germany   Start Trial PRODUCT NAME: MIKROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
C300611 Netherlands   Start Trial PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
2013C/055 Belgium   Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE
47/2013 Austria   Start Trial PRODUCT NAME: OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 (MITTEILUNG) 20130315
PA2013020,C1581254 Lithuania   Start Trial PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
C20130023 00082 Estonia   Start Trial PRODUCT NAME: OKRIPLASMIIN;REG NO/DATE: K(2013)1648 (LOPLIK) 13.03.2013
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
Moodys
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.